Vera Therapeutics (VERA) Restructuring Costs (2020 - 2021)
Vera Therapeutics' (VERA) quarterly Restructuring Costs came in at -$116000.0 in Q4 2021, down 107.34% YoY from $1.6 million in Q4 2020, and down 474.19% on a QoQ basis from $31000.0 in Q3 2021.
Powered by 
Analysis
Vera Therapeutics (VERA) Restructuring Costs (2020 - 2021) Analysis & Trends
Vera Therapeutics (VERA) has 2 years of Restructuring Costs data on file, last reported at -$116000.0 in Q4 2021.
- Quarterly Restructuring Costs fell 107.34% year-over-year to -$116000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $2.9 million (changed N/A YoY) and the FY2020 annual result came in at $3.0 million, changed N/A from the prior year.
- Restructuring Costs eased to -$116000.0 in Q4 2021, from $31000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $1.6 million in Q4 2020 to a low of -$116000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Vera Therapeutics | 2.56 Bn | 2.56 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -116,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Dec 31, 2020 | 1.58 Mn |
| Sep 30, 2020 | 1.42 Mn |